Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome

Annals of Oncology

Volumn 26, Issue 5, 2015, Pages 880-887

  Favero, F ^a,b   McGranahan, N ^a,c   Salm, M ^a   Birkbak, N J ^a,c   Sanborn, J Z ^d   Benz, S C ^d   Becq, J ^e   Peden, J F ^e   Kingsbury, Z ^e   Grocok, R J ^e   Humphray, S ^e   Bentley, D ^e   Spencer Dene, B ^a   Gutteridge, A ^c   Brada, M ^f,g   Roger, S ^h   Dietrich, P Y ⁱ   Forshew, T ^c   Gerlinger, M ^a,j   Rowan, A ^a   Stamp, G ^a   Eklund, A C ^b   Szallasi, Z ^b,k,l   Swanton, Charles ^a,c   more..

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d NantOmics LLC   (United States)

^e ILLUMINA INC   (United States)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

^g CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

ⁱ GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^j INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^k HARVARD MEDICAL SCHOOL   (United States)

^l SEMMELWEIS UNIVERSITY   (Hungary)

more..

Author keywords

Double minute chromosome; Glioblastoma; Intra tumour heterogeneity; Multi region sequencing

Indexed keywords

BEVACIZUMAB; CYCLIN DEPENDENT KINASE 4; IMATINIB; ISOCITRATE DEHYDROGENASE 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P53; TEMOZOLOMIDE; ALKYLATING AGENT; CDK4 PROTEIN, HUMAN; DACARBAZINE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; CDK4 GENE; CHROMOSOME 12; CHROMOSOME 4; DISEASE FREE SURVIVAL; EVOLUTIONARY ADAPTATION; FEMALE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GLIOBLASTOMA; HEADACHE; HISTOPATHOLOGY; HUMAN; IDH1 GENE; INTRACRANIAL HYPERTENSION; KIT GENE; MGMT GENE; MOLECULAR CLONING; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; PDGFRA GENE; PRIMARY TUMOR; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TP53 GENE; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CANCER GRADING; DISEASE COURSE; ENZYMOLOGY; FATALITY; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; HUMAN CHROMOSOME; MUTATION; NEUROSURGERY; PATHOLOGY; PHENOTYPE; TIME FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHROMOSOMES, HUMAN; CYCLIN-DEPENDENT KINASE 4; DACARBAZINE; DISEASE PROGRESSION; FATAL OUTCOME; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GLIOBLASTOMA; HUMANS; IMATINIB MESYLATE; ISOCITRATE DEHYDROGENASE; MUTATION; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEUROSURGICAL PROCEDURES; PHENOTYPE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; TIME FACTORS; TREATMENT OUTCOME;

EID: 84929079389     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv127     Document Type: Article

References (24)

1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359(5): 492-507.
2. Johnson BE, Mazor T, Hong C et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 2014; 343(6167): 189-193.
3. Sottoriva A, Spiteri I, Piccirillo SGM et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA 2013; 110(10): 4009-4014.
4. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009; 174(4): 1149-1153.
5. Turcan S, Rohle D, Goenka A et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012; 483(7390): 479-483.
6. De Bruin EC, McGranahan N, Mitter R et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 2014; 346 (6206): 251-256.
7. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010; 38(16): e164.
8. Yang L, Luquette LJ, Gehlenborg N et al. Diverse mechanisms of somatic structural variations in human cancer genomes. Cell 2013; 153(4): 919-929.
9. Sanborn JZ, Salama SR, Grifford M et al. Double minute chromosomes in glioblastoma multiforme are revealed by precise reconstruction of oncogenic amplicons. Cancer Res 2013; 73(19): 6036-6045.
10. Favero F, Joshi T, Marquard AM et al. Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data. Ann Oncol 2015; 26(1): 64-70.
11. Bolli N, Avet-Loiseau H, Wedge DC et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun 2014; 5: 2997.
12. Jara A, Hanson TE, Quintana FA et al. DPpackage: Bayesian non-and semiparametric Modelling in R. J Stat Softw 2011; 40(5): 1-30.
13. Liu X-Y, Gerges N, Korshunov A et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 2012; 124(5): 615-625.
14. Lovejoy CA, Li W, Reisenweber S et al. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet 2012; 8(7): e1002772.
15. Dewhurst SM, McGranahan N, Burrell RA et al. Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution. Cancer Discov 2014; 4(2): 175-185.
16. Brennan CW, Verhaak RGW, McKenna A et al. The somatic genomic landscape of glioblastoma. Cell 2013; 155(2): 462-477.
17. Bunting SF, Nussenzweig A. End-joining, translocations and cancer. Nat Rev Cancer 2013; 13(7): 443-454.
18. Forment JV, Kaidi A, Jackson SP. Chromothripsis and cancer: causes and consequences of chromosome shattering. Nat Rev Cancer 2012; 12(10): 663-670.
19. Crespo I, Tão H, Nieto AB et al. Amplified and homozygously deleted genes in glioblastoma: impact on gene expression levels. PLoS One 2012; 7(9): e46088.
20. Charitou P, Rodriguez-colman M, Gerrits J et al. FOXOs support the metabolic requirements of normal and tumor cells by promoting IDH 1 expression. EMBO Rep 2015 Feb 3. pii: e201439096 [epub ahead of print].
21. Verhaak RGW, Hoadley KA, Purdom E et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17(1): 98-110.
22. Cerami E, Gao J, Dogrusoz U et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2(5): 401-404.
23. Yap TA, Gerlinger M, Futreal PA et al. Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 2012; 4(127): 127ps10.
24. Lee DH, Amanat S, Goff C et al. Overexpression of miR-26a-2 in human liposarcoma is correlated with poor patient survival. Oncogenesis 2013; 2: e47.